Vitreous proteomics and diabetic retinopathy

Seminars in Ophthalmology

Volumn 25, Issue 5-6, 2010, Pages 289-294

  Walia, Saloni ^a   Clermont, Allen C ^a   Gao, Ben Bo ^a   Aiello, Lloyd Paul ^a   Feener, Edward P ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

diabetic retinopathy; mass spectrometry; proteomics; vitreous

Indexed keywords

ACETAZOLAMIDE; ALPHA 1 ANTITRYPSIN; ALPHA2 GLYCOPROTEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANKYRIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BETA2 GLYCOPROTEIN 1; CARBONATE DEHYDRATASE I; CATALASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C9; ENOLASE; GLUTATHIONE PEROXIDASE; PIGMENT EPITHELIUM DERIVED FACTOR; PROSTAGLANDIN D2; PROSTAGLANDIN H2; SERINE PROTEINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL PERMEABILITY; CILIARY DISK; CLINICAL ASSESSMENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; LEUKOSTASIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RADIOIMMUNOASSAY; REVIEW; TANDEM MASS SPECTROMETRY; THROMBOSIS; VASCULAR LESION; VITREOUS BODY;

DIABETIC RETINOPATHY; EYE PROTEINS; HUMANS; MASS SPECTROMETRY; PROTEOMICS; VITREOUS BODY;

EID: 78649381104     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2010.518912     Document Type: Review

References (34)

1. Scott JE. The chemical morphology of the vitreous. Eye. 1992;6:553-555.
2. Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fbroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol. 1998 Feb;82:181-185.
3. Guidry C, Feist R, Morris R, Hardwick CW. Changes in IGF activities in human diabetic vitreous. Diabetes. 2004 Sep;53:2428-2435.
4. Burgos R, Mateo C, Cantón A, Hernández C, Mesa J, Simó R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000 Jan;23:80-83.
5. Hinton DR, He S, Jin ML, Barron E, Ryan SJ. Novel growth factors involved in the pathogenesis of proliferative vitreo-retinopathy. Eye (Lond). 2002;16:422-428.
6. Katsura Y, Okano T, Noritake M, Kosano H, Nishigori H, Kado S, et al. Hepatocyte growth factor in vitreous fuid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care. 1998;21:1759-1763.
7. Nishimura M, Ushiyama M, Nanbu A, Yoshimura M. Neovascularization and HGF: neovascularization in pro-liferative diabetic retinopathy and intraocular HGF. Rinsho Byori. 1998;46:1156-1161.
8. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, et al. Vascular endothelial growth factor in ocular fuid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
9. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
10. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothe-lial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
11. Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, Wu L, Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116:1481-1487.e1.
12. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145:854-861.
13. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibi-zumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009 Nov;116:2175-2181.e1.
14. Cryan LM and O'Brien C. Proteomics as a research tool in clinical and experimental ophthalmology. Proteomics Clin. Appl. 2008:2;762-775.
15. Rosenblatt BJ, Benson WE. Diabetic retinopathy. In: Yanoff M, Duker JS, editors. Ophthalmology. 2nd ed. vol 2, 2004, 877-886.
16. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol. 2010;2010:840518.
17. Maercker C. Protein arrays in functional genome research. Biosci Rep. 2005.;25:57-70.
18. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng. 2009;11:49-79.
19. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003:13;422:198-207.
20. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res. 2008;7:2516-25.
21. Baldwin MA. Protein identifcation by mass spectrometry: issues to be considered. Mol Cell Proteomics. 2004;3:1-9.
22. Deutsch EW, Lam H, Aebersold R. Data analysis and bioin-formatics tools for tandem mass spectrometry in proteom-ics. Physiol Genomics. 2008;33:18-25.
23. Dubitzky W. Briefngs in bioinformatics. Brief Bioinform. 2009;10:343-344.
24. Gene Ontology Consortium. The Gene Ontology project in 2008. Nucleic Acids Res. 2008;36:D440-4.
25. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.
26. Shimizu A, Nakanishi T, Koyama R, Ikeda T. [Proteomics in clinical research: new approach of mass spectrometry]. Rinsho Byori. 2002;50:169-72.
27. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, et al.Fujimoto. Extracellular carbonic anhy-drase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13:181-188.
28. Kim T, Kim SJ, Kim K, Kang UB, Lee C, Park KS, et al. Profling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics. 2007;7:4203-15.
29. Nakanishi T, Koyama R, Ikeda T, Shimizu A. Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;776:89-100.
30. Simó R, Higuera M, García-Ramírez M, Canals F, García-Arumí J, Hernández C. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fuid and overex-pression in the retina of diabetic patients. Arch Ophthalmol. 2008;126:1076-1081.
31. García-Ramírez M, Canals F, Hernández C, Colomé N, Ferrer C, Carrasco E, et al. Proteomic analysis of human vitreous fuid by fuorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia. 2007;50:1294-1303.
32. Yamane K, Minamoto A, Yamashita H, Takamura H, Miyamoto-Myoken Y, Yoshizato K, et al. Proteome analysis of human vitreous proteins. Mol Cell Proteomics. 2003;2:1177-1187.
33. Kim SJ, Kim S, Park J, Lee HK, Park KS, Yu HG, Kim Y. Differential expression of vitreous proteins in prolif-erative diabetic retinopathy. Curr Eye Res. 2006;31:231-240.
34. Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res. 2005 Aug;81(2):176-182.